AR051888A1 - Anticuerpos frente al receptor alfa -1 de la il-13 y usos de los mismos - Google Patents

Anticuerpos frente al receptor alfa -1 de la il-13 y usos de los mismos

Info

Publication number
AR051888A1
AR051888A1 ARP060100010A ARP060100010A AR051888A1 AR 051888 A1 AR051888 A1 AR 051888A1 AR P060100010 A ARP060100010 A AR P060100010A AR P060100010 A ARP060100010 A AR P060100010A AR 051888 A1 AR051888 A1 AR 051888A1
Authority
AR
Argentina
Prior art keywords
alfa
receiver
same
antibodies against
antibody
Prior art date
Application number
ARP060100010A
Other languages
English (en)
Inventor
Jan Olaf Stracke
Kay-Gunnar Stubenrauch
De Winkel Jan Van
Vugt Martine Van
Sandra Vereecken-Verploegen
Josef Endl
Maria Elena Fuentes
Yvo Graus
Adelbert Grossmann
Sebastian Neumann
Paul Parren
Frank Rebers
Joerg Thomas Regula
Helmut E Schumacher
Stefan Seeber
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR051888A1 publication Critical patent/AR051888A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Un anticuerpo con union a IL-13alfa1, inhibiendo la bioactividad de IL-12 y que contiene unas cadenas variables pesada y ligera, caracterizadas por que la secuencia de aminoácidos de la region variable de la cadena pesada CD3 de dicho anticuerpo es seleccionada a partir del grupo de secuencias de cadena pesada CD3 con Ns de ID SEC: 1, 3, 5, 7 o 9 es util en el tratamiento del asma y las enfermedades respiratorias.
ARP060100010A 2005-01-03 2006-01-03 Anticuerpos frente al receptor alfa -1 de la il-13 y usos de los mismos AR051888A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05000003 2005-01-03
EP05002229 2005-02-03

Publications (1)

Publication Number Publication Date
AR051888A1 true AR051888A1 (es) 2007-02-14

Family

ID=36199730

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060100010A AR051888A1 (es) 2005-01-03 2006-01-03 Anticuerpos frente al receptor alfa -1 de la il-13 y usos de los mismos

Country Status (20)

Country Link
US (2) US7807158B2 (es)
EP (1) EP1836226B1 (es)
JP (1) JP5086098B2 (es)
KR (1) KR100934894B1 (es)
AR (1) AR051888A1 (es)
AT (1) ATE513855T1 (es)
AU (1) AU2006204480B2 (es)
BR (1) BRPI0606368A2 (es)
CA (1) CA2592614C (es)
CR (1) CR9209A (es)
HK (1) HK1112006A1 (es)
IL (1) IL184205A0 (es)
MA (1) MA29226B1 (es)
MX (1) MX2007008128A (es)
NO (1) NO20073655L (es)
NZ (1) NZ556126A (es)
RU (1) RU2413736C2 (es)
SG (1) SG172504A1 (es)
TW (2) TWI306862B (es)
WO (1) WO2006072564A1 (es)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
CA2664343C (en) 2006-10-02 2016-04-26 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human il-4 receptor
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
US8207304B2 (en) 2006-10-19 2012-06-26 Csl Limited Antibody antagonists of interleukin-13 receptor α1
CN101588816B (zh) 2006-10-19 2013-06-19 Csl有限公司 白介素-13受体α1的高亲和性抗体拮抗物
ES2388567T3 (es) 2006-10-19 2012-10-16 Csl Limited Anticuerpos anti-il-13r alfa 1 y usos de los mismos
ES2449148T5 (es) 2007-06-01 2023-06-14 Hoffmann La Roche Purificación de inmunoglobulinas
EP2167127A1 (en) * 2007-07-10 2010-03-31 F. Hoffmann-Roche AG Novel formulation
BRPI0818165B8 (pt) 2007-10-12 2021-05-25 Hoffmann La Roche método de produção recombinante de uma imunoglobulina heteróloga em células cho que é secretada para o meio de cultura
EP2050764A1 (en) * 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
WO2009077127A1 (en) 2007-12-15 2009-06-25 F. Hoffmann-La Roche Ag Distinguishing assay
SG174904A1 (en) * 2009-03-25 2011-11-28 Genentech Inc Anti-fgfr3 antibodies and methods using same
JP5804599B2 (ja) * 2009-05-13 2015-11-04 国立研究開発法人理化学研究所 内臓脂肪型肥満の検査薬およびその利用
MX2012000735A (es) 2009-07-30 2012-01-27 Hoffmann La Roche Separador de columna de cromatografia movible.
CN102574913A (zh) 2009-10-01 2012-07-11 弗·哈夫曼-拉罗切有限公司 多步骤的最终过滤
WO2011038894A1 (en) 2009-10-01 2011-04-07 F. Hoffmann-La Roche Ag Protein a chromatography
SG2014014823A (en) 2009-10-19 2014-07-30 Hoffmann La Roche Non-cross-reactive anti igg antibodies
MY160124A (en) 2009-12-22 2017-02-28 Hoffmann La Roche Sequence dependent aggregation
RU2603284C2 (ru) 2010-08-17 2016-11-27 Ф.Хоффманн-Ля Рош Аг АНТИТЕЛА ПРОТИВ IgG1 ЧЕЛОВЕКА
BR112013017573B1 (pt) 2011-02-02 2021-05-18 F. Hoffmann-La Roche Ag uso de um suporte de coluna de cromatografia, suporte de coluna de cromatografia e dispositivo para suportar coluna de cromatografia
EP2699256B1 (en) 2011-04-21 2017-09-27 The Regents of the University of Colorado, a body corporate Compositions and methods for the treatment of neuromyelitis optica
SG11201500889TA (en) 2012-08-21 2015-03-30 Sanofi Sa Methods for treating or preventing asthma by administering an il-4r antagonist
TWI697334B (zh) 2013-06-04 2020-07-01 美商再生元醫藥公司 藉由投與ｉｌ-４ｒ抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法
TWI709411B (zh) 2013-06-21 2020-11-11 法商賽諾菲生物技術公司 Il-4r拮抗劑用於製備治療鼻息肉症的醫藥品之用途
RU2674996C2 (ru) 2013-07-04 2018-12-14 Ф. Хоффманн-Ля Рош Аг Иммуноферментный анализ с подавлением интерференции для определения антител к лекарствам в образцах сыворотки
TWI634900B (zh) 2013-07-11 2018-09-11 再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
US8986691B1 (en) 2014-07-15 2015-03-24 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US8980273B1 (en) 2014-07-15 2015-03-17 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
CN106029697B (zh) 2013-12-20 2021-06-04 英特维特国际股份有限公司 具有经修饰的ch2-ch3序列的犬抗体
IL315136A (en) 2014-02-21 2024-10-01 Sanofi Biotechnology Methods for treating or preventing asthma by adding an IL-4R antagonist
EP4353254A3 (en) 2014-02-28 2024-07-03 Regeneron Pharmaceuticals, Inc. Methods for treating skin infection by administering an il-4r antagonist
US10550194B2 (en) 2014-09-30 2020-02-04 Intervet Inc. PD-L1 antibodies binding canine PD-L1
EP3218412A1 (en) 2014-11-14 2017-09-20 Sanofi Biotechnology Methods for treating chronic sinusitis with nasal polyps by administering an il-4r antagonist
CA2992420A1 (en) 2015-08-21 2017-03-02 F. Hoffmann-La Roche Ag Method for the reduction of host cell proteins in affinity chromatography
SI3337817T1 (sl) 2015-08-21 2021-12-31 F. Hoffmann - La Roche Ag Postopek za redukcijo beljakovin gostiteljske celice pri afinitetni kromatografiji
US11091556B2 (en) 2015-12-18 2021-08-17 Intervet Inc. Caninized human antibodies to human IL-4R alpha
WO2018011405A1 (en) * 2016-07-15 2018-01-18 Universität Zürich Il-13ralpha1 antibodies for use in treatment of atopic inflammation, sepsis and neutropenia
WO2018045130A1 (en) 2016-09-01 2018-03-08 Regeneron Pharmaceuticals, Inc. Methods for preventing or treating allergy by administering an il-4r antagonist
JOP20190009A1 (ar) 2016-09-21 2019-01-27 Alx Oncology Inc أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها
WO2018057776A1 (en) 2016-09-22 2018-03-29 Regeneron Pharmaceuticals, Inc. Methods for treating severe atopic dermatitis by administering an il-4r inhibitor
TWI784988B (zh) 2016-12-01 2022-12-01 美商再生元醫藥公司 治療發炎症狀的方法
EP3551046B1 (en) 2016-12-07 2023-07-19 Biora Therapeutics, Inc. Gastrointestinal tract detection methods, devices and systems
WO2018183932A1 (en) 2017-03-30 2018-10-04 Progenity Inc. Treatment of a disease of the gastrointestinal tract with a il-13 inhibitor
WO2019028367A1 (en) 2017-08-04 2019-02-07 Regeneron Pharmaceuticals, Inc. METHODS OF TREATING ESOPHAGITIS WITH ACTIVE EOSINOPHILES
PL3703818T3 (pl) 2017-10-30 2024-03-25 Sanofi Biotechnology Antagonista IL-4R do zastosowania w sposobie leczenia lub zapobiegania astmie
JP7393342B2 (ja) 2018-03-21 2023-12-06 エーエルエックス オンコロジー インコーポレイテッド シグナル調節タンパク質αに対する抗体及び使用方法
WO2019222055A1 (en) 2018-05-13 2019-11-21 Regeneron Pharmaceuticals, Inc. Methods for treating atopic dermatitis by administering an il-4r inhibitor
KR20210095165A (ko) 2018-11-19 2021-07-30 프로제너티, 인크. 바이오의약품으로 질환을 치료하기 위한 방법 및 디바이스
BR112021018627A2 (pt) 2019-03-21 2021-11-23 Regeneron Pharma Combinação de inibidores da via de il-4/il-13 e ablação de células plasmáticas para o tratamento de alergia
US20210277131A1 (en) 2019-03-26 2021-09-09 Aslan Pharmaceuticals Pte Ltd TREATMENT EMPLOYING ANTI-IL-l3R ANTIBODY OR BINDING FRAGMENT THEREOF
MX2022001030A (es) 2019-08-05 2022-04-26 Regeneron Pharma Metodos para tratar alergia y mejorar la inmunoterapia especifica de alergenos mediante la administracion de un antagonista de il-4r.
CA3147113A1 (en) 2019-08-05 2021-02-11 Regeneron Pharmaceuticals, Inc. Methods for treating atopic dermatitis by administering an il-4r antagonist
CN115666704A (zh) 2019-12-13 2023-01-31 比奥拉治疗股份有限公司 用于将治疗剂递送至胃肠道的可摄取装置
WO2022186773A1 (en) 2021-03-01 2022-09-09 Aslan Pharmaceuticals Pte Ltd TREATMENT OF ATOPIC DERMATITIS EMPLOYING ANTI-IL-13Rα1 ANTIBODY OR BINDING FRAGMENT THEREOF IN AN ALLERGIC POPULATION
WO2022186772A1 (en) 2021-03-01 2022-09-09 Aslan Pharmaceuticals Pte Ltd TREATMENT OF ATOPIC DERMATITIS EMPLOYING ANTI-IL-13Rα1 ANTIBODY OR BINDING FRAGMENT THEREOF
WO2023048651A1 (en) 2021-09-27 2023-03-30 Aslan Pharmaceuticals Pte Ltd Method for treatment of moderate to severe atoptic dematitis
WO2023048650A1 (en) 2021-09-27 2023-03-30 Aslan Pharmaceuticals Pte Ltd TREATMENT OF PRURITIS EMPLOYING ANTI-IL13Rα1 ANTIBODY OR BINDING FRAGMENT THEREOF
WO2023075702A1 (en) 2021-10-29 2023-05-04 Aslan Pharmaceuticals Pte Ltd Anti-il-13r antibody formulation
WO2024043837A1 (en) 2022-08-26 2024-02-29 Aslan Pharmaceuticals Pte Ltd High concentration anti-il13r antibody formulation
WO2024054157A1 (en) 2022-09-06 2024-03-14 Aslan Pharmaceuticals Pte Ltd Treatment for sleep loss or sleep disturbance in patients with dermatitis

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5614191A (en) 1995-03-15 1997-03-25 The United States Of America As Represented By The Department Of Health And Human Services IL-13 receptor specific chimeric proteins and uses thereof
CA2238080C (en) 1995-10-23 2012-03-13 Amrad Operations Pty. Ltd. A novel haemopoietin receptor and genetic sequences encoding same
US5843659A (en) * 1996-03-21 1998-12-01 Apoptosis Technology, Inc. Apoptosis gene EI24, compositions, and methods of use
JPWO2003046009A1 (ja) * 2001-11-27 2005-04-07 持田製薬株式会社 抗ＩＬ１３レセプターα１中和抗体
AR037756A1 (es) * 2001-12-17 2004-12-01 Bayer Corp Anticuerpo que inhibe la actividad del factor de las celulas precursoras y su uso para el tratamiento del asma.
JP4432031B2 (ja) 2002-03-22 2010-03-17 ズィナイス オペレーションズ ピーティーワイ．エルティーディー． インターロイキン１３受容体α１（ＩＬ−１３Ｒα１）に対するモノクローナル抗体
US7625699B2 (en) * 2003-03-10 2009-12-01 Celera Corporation Genetic polymorphisms associated with coronary stenosis, methods of detection and uses thereof
MXPA06000583A (es) * 2003-07-15 2006-03-30 Amgen Inc Anticuerpos neutralizantes anti-ngf humano como inhibidores selectivos de la via del ngf.

Also Published As

Publication number Publication date
CA2592614A1 (en) 2006-07-13
IL184205A0 (en) 2007-10-31
TWI306862B (en) 2009-03-01
SG172504A1 (en) 2011-07-28
JP5086098B2 (ja) 2012-11-28
TW200902555A (en) 2009-01-16
NZ556126A (en) 2008-09-26
EP1836226A1 (en) 2007-09-26
KR20070091180A (ko) 2007-09-07
MA29226B1 (fr) 2008-02-01
WO2006072564A1 (en) 2006-07-13
CA2592614C (en) 2015-04-14
TW200635945A (en) 2006-10-16
CR9209A (es) 2007-08-28
HK1112006A1 (en) 2008-08-22
US7807158B2 (en) 2010-10-05
EP1836226B1 (en) 2011-06-22
KR100934894B1 (ko) 2010-01-07
RU2007129676A (ru) 2009-02-10
ATE513855T1 (de) 2011-07-15
US20060263356A1 (en) 2006-11-23
NO20073655L (no) 2007-08-02
AU2006204480A1 (en) 2006-07-13
RU2413736C2 (ru) 2011-03-10
US20110086026A1 (en) 2011-04-14
BRPI0606368A2 (pt) 2009-06-23
MX2007008128A (es) 2007-07-20
AU2006204480B2 (en) 2011-06-09
JP2008526187A (ja) 2008-07-24

Similar Documents

Publication Publication Date Title
AR051888A1 (es) Anticuerpos frente al receptor alfa -1 de la il-13 y usos de los mismos
CO6220978A2 (es) Anticuerpos dirigidos a proteina-1 quimio-tactica de monocitos (mcp-1)y sus usos
HK1071586A1 (en) Transplant acceptance inducing cells of monocytic origin and their preparation and use
PE20141166A1 (es) Anticuerpos anti-angptl3 y usos de los mismos
ES2689746T3 (es) Anticuerpos monoclonales contra la claudina-18 para el tratamiento de cáncer
ATE403680T1 (de) Herstellung tetravalenter antikörper
PE20080035A1 (es) Anticuerpos monoclonales humanos para la quinasa-1 tipo receptor de activina
AR071510A1 (es) Anticuerpos anti- factor d humanizados y sus usos
EA200800812A1 (ru) Композиции антитела против cd3
AR065921A1 (es) Anticuerpos anti-ige
ECSP14011269A (es) Formulaciones de anticuerpos y proteínas de alta concentración
AR075790A2 (es) Anticuerpos anti -ngf humanos neutralizantes como inhibidores selectivos de la via de ngf (factor de crecimiento neural)
RS54111B1 (en) ANTI-ALPHA 2 INTEGRIN ANTIBODIES AND THEIR USES
EA201070730A1 (ru) Гуманизированные антитела, специфичные к фактору фон виллебранда
PE20121361A1 (es) Antagonistas de pcsk9
NZ623319A (en) Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
RS52782B (en) HIGH AFINITY HUMAN ANTIBODIES FOR THE HUMAN IL-4 RECEPTOR
NZ597676A (en) Crystalline anti-hTNFalpha antibodies
CO5700152A1 (es) Nuevos anticuerpos anti-igf-ir y sus usos
PE20061395A1 (es) Anticuerpos contra miostatina
RU2015147300A (ru) Гуманизированные антитела к cxcr5, их производные и их применение
PE20080036A1 (es) Anticuerpos humanos para la interleucina-13 (il13)
AR058983A1 (es) Metodos y composiciones para el tratamiento de enfermedades alergicas
CO6230999A2 (es) Anticuerpo anti-esclerostina
PE20030282A1 (es) Anticuerpos de interleucina-1- beta

Legal Events

Date Code Title Description
FB Suspension of granting procedure